A Phase III Study of GS101 Injection to Dupixent®

Summary

This is a a multicenter, randomized, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis. A total of 572 subjects are planned to be included and randomized at a ratio of 1:1 to receive GS101 injection or Dupixent®

Timeline

Start

2026-02

Primary completion

2027-04

Completion

2028-01

Drugs

Indications